Combined treatment using adenoviral-directed enzyme/prodrug therapy and immunotherapy has the potential to become a powerful alternative method of cancer therapy. We have developed adenoviral vectors encoding the cytosine deaminase gene (Ad-CD) and cytosine deaminase:uracil phosphoribosyltransferase fusion gene (Ad-CD:UPRT). A monoclonal antibody, TRA-8, specifically binds to death receptor 5, one of two death receptors bound by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). The purpose of this study was to evaluate cytotoxicity in vitro and therapeutic efficacy in vivo of the combination of Ad-CD:UPRT and TRA-8 against human pancreatic cancer and glioma cell lines. The present study demonstrates that Ad-CD:UPRT infection resulted in increased 5-FC-mediated cell killing, compared with Ad-CD. Furthermore, a significant increase of cytotoxicity following Ad-CD:UPRT/5-FC and TRA-8 treatment of cancer cells in vitro was demonstrated. Animal studies showed significant inhibition of tumor growth of MIA PaCa-2 pancreatic and D54MG glioma xenografts by the combination of Ad-CD:UPRT/5-FC plus TRA-8 as compared with either agent alone or no treatment. The results suggest that the combination of Ad-CD:UPRT/5-FC with TRA-8 produces an additive cytotoxic effect in cancer cells in vitro and in vivo. These data indicate that combined treatment with enzyme/prodrug therapy and TRAIL immunotherapy provides a promising approach for cancer therapy.
Introduction
Resistance to chemotherapeutic drugs is a major obstacle in cancer therapy. Resistance can take place at the beginning of treatment as well as develop through a selection of a subpopulation of resistant cells during chemotherapy. Strategies for overcoming resistance are essential to the success of cancer therapy. Combined treatment using adenoviral-directed prodrug-activating enzyme gene transduction and immunotherapy has the potential to become a powerful alternative method for cancer therapy.
One of the most widely investigated suicide gene/ prodrug systems is cytosine deaminase/5-fluorocytosine (CD/5-FC) that has been studied intensely during the last decade. CD is a bacterial or yeast enzyme that can convert the antifungal agent 5-FC into the chemotherapeutic agent 5-fluorouracil (5-FU). Importantly, 5-FU is able to diffuse across the cell membrane into adjacent cells without going through the gap junctions, resulting in a more powerful bystander effect. 1, 2 However, certain cancers demonstrate relative resistance to 5-FU, because of the poor efficiency of conversion of 5-FU into its toxic metabolites. Escherichia coli (E. coli) uracil phosphoribosyltransferase (UPRT) is a pyrimidine salvage enzyme that catalyzes the synthesis of uridine 5'-monophosphate (UMP). As 5-FU is directly converted into 5-FUMP by UPRT in microorganisms, transfer of UPRT into tumor cells reportedly induces a more efficient conversion of 5-FU into 5-FUMP, which results in enhanced cytotoxicity of 5-FU. 3, 4 Furthermore, a combination of UPRT with the CD/5-FC system has been reported to increase 5-FC killing of cells. [5] [6] [7] Recent studies have demonstrated that death receptor 5 (DR5), one of two death receptors bound by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), showed increased expression on most malignantly transformed cells. DR5-positive cancer cells can be killed by a novel agonistic anti-DR5 antibody, TRA-8, which binds specifically to DR5. This agent demonstrated the capability to activate proapoptotic signal transduction and induce cancer cell killing. Importantly, this antibody does not produce cytotoxicity to normal cells, including hepatocytes in vitro. 8 The TRA-8 antibody in combination with certain chemotherapeutic agents, proapoptotic bax gene delivery, and ionizing radiation demonstrated synergistic antitumor activity in vitro and in vivo. 9, 10 The aim of this study was to investigate whether a combination of apoptosis-inducing antibody treatment with adenoviral-mediated suicide gene expression and prodrug therapy produces increased cytotoxicity against cancer cells. In vivo studies using human pancreatic cancer and glioma xenografts in nude mice examined the therapeutic efficacy of CD:UPRT/5-FC therapy alone or in combination with TRA-8 treatment. The results demonstrate that TRA-8 antibody is able to enhance CD:UPRT/5-FC-mediated cytotoxicity of pancreatic cancer and glioma cells and increase antitumor efficacy in cancer xenograft models in vivo.
Materials and methods
Tumor cells, animals, chemicals, antibodies, and recombinant adenoviruses (Ads) Human glioma cell lines D54MG (a kind gift from Dr GY Gillespie, University of Alabama at Birmingham, Birmingham, AL), U87MG (American Type Culture Collection, Manassas, VA), and human embryonic kidney HEK293 cells (Microbix Biosystems Inc., Ontario, Canada) were cultured in DMEM/F12 (Mediatech, Herndon, VA) containing 10% fetal bovine serum (FBS) (Summit Biotechnology, Fort Collins, CO). Human pancreatic BxPc-3 and MIA PaCa-2 carcinoma cell lines (American Type Culture Collection) were maintained in RPMI 1640 (Mediatech) containing 10% FBS. All cells were cultured at 371C in a 5% CO 2 atmosphere without antibiotics.
Female nude athymic mice were purchased from the Frederick Cancer Research Facility (Bethesda, MD) and housed under aseptic conditions in microisolator cages and experiments were carried out according to the Institutional Animal Care and Use Committee approved protocols.
An anti-human DR5 mouse monoclonal antibody, TRA-8, was provided by Sankyo Co., Ltd (Tokyo, Japan). Anticaspase-8, -9 and Poly(ADP-ribose) polymerase (PARP)-specific mouse monoclonal antibodies and anti-caspase-3 rabbit polyclonal antibody were provided by BD Biosciences Pharmingen (San Diego, CA). Goat anti-mouse Ig(H þ L)-HRP antibody was provided by Southern Biotechnology Associates (Birmingham, AL). 5-FC, 5-FU, 3 H-5-FC and A replication-deficient E1-and E3-deleted Ad-CD recombinant adenoviral vector encoding the CD gene (codA), under control of the human cytomegalovirus (CMV) immediate early promoter, was constructed by two-plasmid rescue in HEK293 cells using pACCMVpLpA shuttle vector and pJM17 rescue vector as described previously.
11 A replication-deficient E1-and E3-deleted Ad-CD:UPRT recombinant adenoviral vector encoding the CD:UPRT (codA:upp) fusion genes (InvivoGen, San Diego, CA) driven by the CMV promoter was developed using pAdEasy system (Quantum Biotechnologies, Montreal, Canada) as per the manufacturer's protocol. AdCMVEGFP recombinant Ad (encoding enhanced green fluorescent protein (EGFP) gene under control of the human CMV promoter element) was kindly provided by Dr CR Miller (Washington University, St Louis, MO). Viruses were propagated on permissive HEK293 cells and purified twice by centrifugation on CsCl gradients. Viral titer was measured by a standard 50% tissue culture infectious dose (TCID 50 ) assay using HEK293 cells and by absorbance of the dissociated virus at A 260 nm . Multiplicity of infection (MOI) for subsequent experiments was expressed as TCID 50 per cell.
In vitro cytotoxicity assay
To measure the toxicity of 5-FU and TRA-8, cancer cells were plated into 96-well tissue culture plates at 5000 cells/ well, and allowed to adhere overnight. Next day, serial dilutions of 5-FU or TRA-8 were added directly to cells. Cells were incubated for 5 days, and relative cell density was determined using the crystal violet staining assay. Fractional cell survival at each drug concentration was calculated as the ratio of absorbance at 570 nm of cells incubated in the presence versus absence of drug, corrected for background absorbance of media alone. Fractional cell survival data were plotted against drug concentration and IC 50 values extrapolated by piecewise linear regression as the concentration of drug producing a 50% reduction in corrected absorbance.
For Ad-CD/5-FU and Ad-CD:UPRT/5-FU cytotoxicity experiments, the target cells were plated into 96-well tissue culture plates at 5000 cells/well, and allowed to adhere overnight. After 24 h, cells were infected with Ad-CD or Ad-CD:UPRT at various MOI. Next day fresh media supplemented with serial dilutions of 5-FU were added, and 5-FU cytotoxicity (IC 50 ) was determined at 5 days using the crystal violet staining assay.
To determine Ad-CD/5-FC and Ad-CD:UPRT/5-FC cytotoxicity, cells were treated as described above. The serial dilutions of 5-FC were added 24 h after adenoviral infection, and 5-FC cytotoxicity (IC 50 ) was determined at 5 days using the crystal violet staining assay.
CD conversion assay MIA PaCa-2 and D54MG cancer cells were seeded into 25 cm 2 flasks, 24 h prior to infection. Cells were exposed to Ad-CD or Ad-CD:UPRT recombinant adenoviruses at 100 MOI for 2 h, culture medium was removed and fresh medium was added. After 48 h, the cells were trypsinized and resuspended in CD lysis buffer (100 mM Tris, 1 mM EDTA, 1 mM DTT, pH 7.8). Cells were frozen and thawed three times, and after centrifugation the supernatant was assayed for protein concentration (Bio-Rad Laboratories, Hercules, CA). To start each reaction, 3 H-5-FC was added. After various time points, the reactions were stopped with the addition of 95% ethanol. 5-FC/5-FU (Pharmacia, Peapack, NJ) standards were added to each tube and the whole sample spotted on silica gel plates for TLC (Whatman, Clifton, NJ). These were run in 86:14 butanol:water to separate the 5-FU (top) from the 5-FC (bottom) spots and all were cut out and put into scintillation fluid for at least 2 h, and counted using a 1900 TR Liquid Scintillation Analyzer (Packard Instrument Co., Downers Grove, IL). To determine the specific activity of samples, 5-FU formed (nmol) was plotted against time. The slope of the graph (nmol formed per min) was then divided by the amount of protein used to obtain the CD activity (expressed as nmol/min/mg protein).
UPRT conversion assay MIA PaCa-2 and D54MG cancer cells were seeded into 25 cm 2 flasks, 24 h prior to infection. Cells were exposed to Ad-CD:UPRT recombinant adenovirus at 100 MOI for 2 h, culture medium was removed and fresh medium was added. After 48 h, the cells were trypsinized and resuspended in UPRT lysis buffer (50 mM Tris-HCl, 1 mM DTT, 5 mM MgCl 2 , pH 8.0). Cells were frozen and thawed three times, and after centrifugation the supernatant was assayed for protein concentration (Bio-Rad). Samples were incubated with 2 mM 5-phosphorylribose 1-pyrophosphate, sodium salt (PRPP, Sigma), and 1 mM GTP at 371C for 5 min. To start each reaction, 3 H-5FU was added. After various time points, the reactions were stopped with the addition of 95% ethanol. 5-FU/ 5-FUMP (Moravek Biochemicals, Brea, CA) standards were added to each tube and the whole sample spotted on cellulose TLC plates (Selecto Scientific Inc., Suwanee, GA). These were run in 1:1 methanol:water to separate the 5-FUMP (top) from the 5-FU (bottom) spots and all were cut out and put into scintillation fluid, and counted using a 1900 TR Liquid Scintillation Analyzer (Packard). To determine the specific activity of samples, 5-FUMP formed (nmol) was plotted against time. The slope of the graph (nmol formed per min) was then divided by the amount of protein used to obtain the UPRT activity (expressed as nmol/min/mg protein).
Flow cytometry
Annexin V staining and propidium iodide (PI) uptake were used for apoptosis evaluation. MIA PaCa-2 and D54MG cancer cells were infected with 50 MOI of Ad-CD:UPRT and allowed to incubate overnight. Next day, 5-FC was added to cell culture media in final concentration of 12 mg/ml. After 48 h, 50 ng/ml TRA-8 was added and cells were incubated overnight. Cells were collected and double stained with FITC-conjugated annexin V and PI. Annexin V and PI were added according to the manufacturer's recommendations (BioVision, Palo Alto, CA). Samples were immediately analyzed by FACScan. Annexin V and PI emissions were detected in the FL-1 (530/30 nm) and FL-2 (585/40 nm) channels, respectively. For each sample, data from approximately 10 000 cells were recorded in list mode on logarithmic scales. Analysis was performed with Cell Quest software (Becton Dickinson, San Jose, CA) on cells characterized by forward/side scatter (FSC/SSC) parameters. Cell debris characterized by a low FSC/SSC was excluded from analysis. Annexin V-positive and PI-negative cells were considered apoptotic, cells taking only vital dye PI were considered necrotic. The percentages of apoptotic cells were calculated.
EGFP expression assay Cellular EGFP expression was quantitatively examined by FACS analysis and visualized using fluorescent microscopy. Cells were collected 48 h after AdCMVEGFP infection and approximately 10 000 cells were illuminated at 488 nm and fluorescence was detected in the FITC (525/20 nm) channel. Nonspecific fluorescence was detected using a 575/30 nm emission filter in the PI channel. EGFP fluorescence is expressed as the mean fluorescence signal in EGFP-positive cells in relative units (ru) after subtraction of background fluorescence. An Olympus IX70 inverted microscope system (Olympus America, Melville, NY) was used for screening of EGFP expression in cell monolayers.
Western blot
The specific proteolysis of caspase-3, -8 and -9, and PARP were examined by Western blot technique. Briefly, MIA PaCa-2 and D54MG cancer cells were infected with 100 and 50 MOI of Ad-CD:UPRT, respectively, and 5-FC was added to cell culture media in final concentration of 24 and 6 mg/ml for MIA PaCa-2 and D54MG cells, respectively. TRA-8 in final concentration of 50 ng/ml was added to cell culture media 24 or 48 h after infection of MIA PaCa-2 and D54MG cells, respectively. Cells were collected 8 h after treatment with TRA-8 antibody, washed in Tris-buffered solution (TBS), and homogenized in lysis buffer. Each sample was denatured for 5 min at 1001C in loading buffer. Equal amounts of protein were loaded for each sample in all lanes and separated on SDS-PAGE followed by transfer to a PVDF membrane. The membrane was blocked with 5% nonfat milk in TBS. The membrane was incubated with specific and secondary antibodies, and then processed and treated with ECL plus Western Blotting Detection System (Amersham Biosciences, Little Chalfont Buckinghamshire, UK). For immunodetection of caspase-3, the WesternBreeze Chemiluminescent Western Blot Immunodetection Kit (Invitrogen, Carlsbad, CA) was used. 
In vivo study

Statistical analysis
All error terms are expressed as the standard deviation of the mean. Significance levels for comparison of differences between groups in the in vitro experiments were analyzed by Student's t-test. The differences were considered significant when P-value was o0.05. All reported P-values are two-sided. To calculate combined Ad-CD:UPRT/5-FC and TRA-8 cytotoxic effects, the combination index isobologram method was used. 12, 13 Briefly, this method defines the expected additive effect of combined agents and then quantifies the degree of enhancement/reduction of effect by determining how much the combination effect differs from the expected additive effect using the combination index. The combination index equation takes into account both the potency and the shape of the dose-effect curves. In this analysis, synergy is defined as mean combination index values significantly less than 1.0, antagonism as mean combination index values significantly greater than 1.0, and additivity as mean combination index values not significantly different from 1.0. In the animal model tumor therapy studies, the treatment groups were compared with respect to tumor size and percent of original tumor size over time, and complete tumor regressions. To test for significant differences in tumor size between treatment groups, one-way analysis of variance (ANOVA) test was conducted. When the ANOVA indicated that a significant difference existed (P-value o0.05), multiple comparison procedures were used to determine where the differences lay.
Results
5-FU sensitivity in vitro
To determine the sensitivity of cancer cells to 5-FU, pancreatic cancer and glioma cells were treated with various concentrations of 5-FU, and the cytotoxicity of this drug was determined by measuring surviving cells using the crystal violet staining method. As shown in Figure 1a , the viability of cells treated with 5-FU decreased proportional to the increasing amount of 5-FU used. The susceptibility to cytotoxic effects of 5-FU was variable in different cancer cell lines. The concentration of 5-FU to produce 50% viable cells (IC 50 ) was 0.2 mg/ml for BxPc-3 pancreatic cancer cells and 7.1 mg/ml for D54MG glioma cells (Figure 1a) . The relative sensitivity to 5-FU treatment was BxPc-3 4MIA PaCa-2 4U251MG XD54MG.
TRA-8-mediated cytotoxicity Next, we examined the cytotoxic effect of TRA-8 antibody against cancer cells in vitro. Pancreatic and glioma cancer cells were incubated with different concentrations of TRA-8, and the cell viability was determined by measuring surviving cells using the crystal violet staining method (Figure 1b) . Cell killing was proportional to the concentration of TRA-8 used, and the range of IC 50 was from 10.5 ng/ml for MIA PaCa-2 pancreatic cancer cells to 73.0 ng/ml for BxPc-3 cell line (Figure 1b ). U251MG cells showed less than 25% killing at the highest (400 ng/ml) dose of TRA-8 tested. The relative sensitivity to TRA-8 treatment was MIA PaCa-2 XD54MG 4BxPc-3 4U251MG.
Combined treatment with TRA-8 and 5-FU enhances cancer cell killing
The purpose of the next study was to investigate whether combined treatment with TRA-8 and 5-FU produces increased cytotoxicity of cancer cells in vitro. MIA PaCa-2 pancreatic cancer cells and D54MG glioma cells were treated with TRA-8 antibody at 3 and 12 ng/ml, respectively, which produced moderate cell killing (23% for MIA PaCa-2 cells and 39% for D54MG cells). As shown in Figure 1c , the combination of 5-FU and TRA-8 produced enhanced cell death in comparison with treatment using either of these agents alone. The mean IC 50 with 5-FU was 1.1 mg/ml for MIA PaCa-2 cells that received combined treatment in comparison with 2.6 mg/ml for 5-FU-alone-treated cells, and 1.4 mg/ml for D54MG cells treated with 5-FU in combination with TRA-8 antibody in comparison with 7.1 mg/ml for 5-FUtreated D54MG cells. A similar tendency of increased cell killing following combined treatment with TRA-8 and 5-FU was obtained with BxPc-3 and U251MG cells (data not shown). Effect of combined therapy of D54MG glioma xenografts Additionally, we determined whether combination Ad-CD:UPRT/5-FC with TRA-8 treatment inhibited D54MG tumor growth (Figure 3b) . The baseline mean and standard deviation for tumor sizes at 10 days post tumor cell injection was 178755 mm 2 and were not significantly different between treatment groups (P40.05). In vivo tumor therapy was initiated on day 0, which corresponded to 10 days post tumor cell injection. There were no significant differences in tumor growth between groups that received Ad-CD:UPRT plus TRA-8 and 
Discussion
Chemotherapy is widely used with surgery and radiotherapy for the treatment of cancer. Selectivity of most drugs for malignant cells remains elusive. In this study, glioma and pancreatic cancer cell lines were used because these cancers are resistant to conventional treatments. [14] [15] [16] Unfortunately, an insufficient therapeutic index, a lack of specificity, and the emergence of drug-resistant cell subpopulations often hamper the efficacy of drug therapies. A major problem for cancer treatment is the presence of toxic side effects associated with chemotherapeutic agents that limit their efficacy. The heterogeneity of the tumor cell population is another major drawback. There is a need for the development of new alternative therapeutic strategies. Among these approaches, genedirected enzyme-prodrug therapy using the CD/5-FC system has been developed. In this methodology, the codA gene encoding for an enzyme that converts the 5-FC prodrug to 5-FU is delivered to the target cells, resulting in their death. Although this approach has been in development for a long time, new combinations with other cancer therapies, such as selective conventional chemotherapy and radiotherapy, are currently being tested. [17] [18] [19] [20] The efficacy of standard chemotherapy tends to be limited by development of resistance to treatment.
A number of studies elucidated the mechanisms for the development of resistance to 5-FU treatment. These include rapid degradation of 5-FU to nontoxic derivatives through the action of dihydropyrimidine dehydrogenase (uracil reductase), 21, 22 different expression levels of enzymes involved in 5-FU phosphorylation, 23 and amplification of the gene encoding thymidylate synthase (TS) 24, 25 or reduction in the synthesis of folylpolyglutamine. 26 Also, poor efficiency of conversion of 5-FU into its toxic metabolites plays an important role in resistance to 5-FU cancer therapy. In mammalian cells, which appear to lack UPRT, 5-FU is converted into 5-FdUMP via a two-step procedure that is activated only when 5-FU is present at high intracellular concentrations. E. coli UPRT is a pyrimidine salvage enzyme that catalyzes the synthesis of UMP, a precursor for pyrimidine nucleotide, from uracil and 5-phosphoribosyl a-diphosphate (PRPP). Since 5-FU is directly converted into 5-FUMP by UPRT in microorganisms, transfer into tumor cells of this gene should induce a more efficient conversion of 5-FU into 5-FUMP, thus restoring cell sensitivity to 5-FU. 27 The prodrug activation system formed by the codA gene encoding CD and 5-FC developed for selective cancer chemotherapy suffers from a sensitivity limitation in many tumor cells. In an attempt to improve the CD/5-FC suicide efficiency, we combined the upp gene encoding UPRT with the codA gene to create the situation prevailing in E. coli, a bacterium very efficient in metabolizing 5-FC. The results of our studies demonstrated that the Ad-CD:UPRT-mediated expression of codA and upp fusion genes in cancer cells generated a cooperative effect resulting in enhanced 5-FC sensitivity of cells compared to the expression of codA alone.
In the present study, we investigated codA:upp fusion gene transfer in an adenovirus-directed enzyme/prodrug approach for treatment of pancreatic cancer and glioma cells in vitro and in vivo. The rationale for using the codA:upp fusion gene was that the CD would convert 5-FC to 5-FU, which would then be converted by UPRT to its active metabolites, thus, increasing the antitumor activity. Also as UPRT has been shown to enhance 5-FU mediated cytotoxicity, we compared the relative antitumor effects of the following enzyme/prodrugs combinations, CD:UPRT/5-FC, CD:UPRT/5-FU, as well as the conventional CD/5-FC and CD/5-FU.
Since one of the major limitations in current cancer gene therapy is the poor efficacy of in vivo gene transfer, successful application of a suicide gene will depend on its bystander killing effect. In the CD/5-FC system, the bystander effect is caused by the passive diffusion of 5-FU into the extracellular milieu and its diffusion into the adjacent cells, which requires no gap junctions. 28 On the other hand, transport of the 5-FU metabolites is thought to occur through gap junctions. 29 Recently, it has been shown that the bystander effect of the CD:UPRT/5-FC treatment was weaker in comparison with the CD/5-FC system. 2 However, a previous report of treatment for experimental glioma by means of the same system as used here showed that the combination with UPRT/5-FC produced a better bystander effect than CD/5-FC alone. 6 In the present study, a more potent cytotoxic effect was obtained using Ad-CD:UPRT/5-FC treatment in comparison with Ad-CD/5-FC for both human glioma and pancreatic cancer cell lines. Ad-CD and Ad-CD:UPRT comparative study showed significant decreased CD conversion in Ad-CD:UPRT-treated cells. These data demonstrate that the addition of the upp gene could account for the enhanced cytotoxicity because following CD conversion of 3 H-5-FC into 3 H-5-FU, this metabolite was rapidly converted by UPRT to 3 H-FUMP detected in the UPRT conversion assay, which is an irreversible inhibitor of TS and thus inhibits DNA synthesis by deoxythymidine triphosphate deprivation. 18 The simultaneous expression of codA and upp genes generated a cooperative effect resulting in a dramatic increase in 5-FC sensitivity of infected cells compared to the expression of codA alone. The cytotoxic effect of 5-FU is largely exerted following its conversion to 5-FdUMP and 5-FUTP. 5-FdUMP irreversibly inhibits TS, which subsequently prevents DNA synthesis. On the other hand, 5-FUTP can be incorporated into RNA (F-RNA) instead of uridine 5-triphosphate to inhibit the nuclear processing of rRNA and mRNA.
Recent studies demonstrated that TRA-8 monoclonal antibody induces apoptosis of most TRAIL-sensitive tumor cells both in vitro and in vivo. In contrast to the membrane-bound form of human TRAIL, which induced severe hepatitis in mice, and the soluble form of human TRAIL, which induced apoptosis of normal human hepatocytes in vitro, TRA-8 did not induce significant cell death of normal human hepatocytes. 8 Also, treatment with TRA-8 alone or in combination with gene therapy, chemotherapy and/or radiation demonstrated significant antitumor efficacy in breast cancer 9 and glioma 10 xenograft models. The results of this study indicated that Ad-CD:UPRT/ 5-FC therapy in combination with TRA-8 monoclonal antibody treatment produced increased cytotoxicity in comparison with Ad-CD:UPRT/5-FC alone or TRA-8 plus Ad-CD:UPRT. The molecular pathways that mediate the CD:UPRT/5-FC plus TRA-8 therapy-induced cell death remains to be elucidated. The induction of apoptosis and the role of caspases in CD:UPRT/5-FC gene therapy in combination with TRA-8 using human malignant pancreatic cancer and glioma cells was examined. These data demonstrate that apoptosis induced by Ad-CD:UPRT and TRA-8 antibody in pancreatic cancer and glioma cells is dependent on the activation of the caspase pathway. Also, the combination of TRA-8 treatment with expression of a suicide gene using Ad-CD:UPRT provided additive effects in cancer cells.
Thus, the apoptosis induced by 5-FC may be a primary mechanism in CD:UPRT gene therapy of pancreatic cancer and glioma cells. These data agree with observations that induction of apoptosis, DNA damage, activation of mitochondrial caspase pathway involving caspases-3 and -9, and inhibition of TS and DNA synthesis are associated with CD/5-FC-mediated glioma 30 and pancreatic 31 cancer cell killing. Combined treatment using Ad-CD:UPRT-mediated coda:upp suicide genes with TRA-8, which strongly induces apoptosis of most TRAIL-sensitive tumor cells both in vitro and in vivo, 8, 10, 32 led to an enhanced and sustained activation of apoptosis in cancer cells.
Recently, a number of studies demonstrated that combined treatment with TRAIL and 5-FU led to increased suppression of tumor growth and regression of some tumors. The crosssensitization between TRAIL and 5-FU for induction of the apoptotic pathway through caspase activation depends on the expression of the proapoptotic bax gene. [33] [34] [35] [36] Additionally, previous reports have demonstrated that chemotherapeutic agents can induce increased DR5 expression, [37] [38] [39] and it has been proposed that this may be a possible mechanism by which enhanced killing by TRAIL could occur following combined treatment.
The The results suggest that the combination of Ad-CD:UPRT with TRA-8 produces an additive cytotoxic effect in pancreatic cancer and glioma cells in vitro and in vivo. Agonistic monoclonal antibodies specific for TRAIL-R2 can surmount resistance to adenoviral-mediated overexpression of suicide enzymes in some pancreatic cancer and glioma cell lines. In summary, these studies indicate that treatment using suicide gene/5-FC prodrug therapy in combination with TRA-8 anti-DR5 antibody provides a promising approach for cancer therapy.
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